
Treatment-emergent adverse events associated with Rebyota for Clostridioides difficile infection were more prevalent in those with renal comorbidities than in those without and were moderate in severity as well as related to pre-existing conditions.

Treatment-emergent adverse events associated with Rebyota for Clostridioides difficile infection were more prevalent in those with renal comorbidities than in those without and were moderate in severity as well as related to pre-existing conditions.

Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses being the second pharmacist in IDSA history to receive a society award and what this means not only for her, but for the field.